| |
|
|
|
Oxford Global , London
2016-04-18
Day 1 Stream 1 – Antibody Discovery & Engineering - Moving beyond mAbs: novel bispecific formats and ADCs
- Novel ADC payloads and conjugation techniques
- Antibody pharmacokinetics (PK) and Pharmacodynamics (PD)
- New antibody discovery platforms
- Single domain and recombinant antibody tools
Day 1 Stream 2 – Protein Expression & Characterisation - Emerging technologies for protein expression: imaging tools, nanodiscs and NMR
- Membrane proteins as key drug targets: overcoming purification and expression hurdles
- The latest updates in protein science:
- proteomics
- folding
- pathway engineering
- protein modification
- Designing the right proteins: combatting cost of goods with early stage drug design
Day 2 Stream 1 – Therapeutic Applications of Antibodies- Novel bispecific antibodies and their therapeutic potential
- Next-generation affinity reagents: recombinant and engineered antibodies, nucleic acid aptamers
- Immuno-oncology: the latest research in targeting solid tumours
- Alternative scaffolds and novel antibody formats
Day 2 Stream 2 – Protein Purification & Downstream Processing- Reducing protein production timelines with cell line development and novel disposable technologies
- Obtaining reference standards for therapeutic proteins
- Protein stability in pharmaceutical manufacturing:
- storage concerns
- extending ‘shelf life’
- Automation and robotics to enhance processing
|
|
|
|
|
|
|
|
Organized by:
|
|
Oxford Global |
|
|
Invited Speakers:
|
|
- Michel Awwad
Senior Director, Merrimack - Frank Comer
Principal Scientist, MedImmune - Tapan Das
Director, BMS - Rakesh Dixit
VP R&D Head Biologics Safety Assessment, MedImmune - Per-Ola Freskgard
Vice Director and Senior Leader, Neuroscience, Roche Innovation Center Basel - Rajiv Gangurde
Associate Director, Protein Production, Genocea Biosciences - Changshou Gao
Fellow, R&D, Department of Antibody Discovery & Protein Engineering, MedImmune LLc - Steve Hall
Director of Pfizer Regulatory Strategy, Pfizer Worldwide Research and Development - Haruki Hasegawa
Principal Scientist, Therapeutic Discovery, Amgen - Guna Kannan
Principal Scientist, Amgen - Bernardo Perez-Ramirez
Senior Scientific Director, Genzyme - Bianka Prinz
Senior Scientist, Adimab - Yang Shen
Research Advisor, Eli Lilly - Binesh Shrestha
Lab Head, Novartis - Annelise Vuidepot
Head of Protein Science, Immunocore - Mark Wilson
Head of Downstream Development, Novartis Vaccines and Diagnostics
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
ASAP
|
|
|
|
|
|
|
|
Registration:
|
|
Contact Danielle Dalby today for further information regarding registration for this congres. d.dalby@oxfordglobal.co.uk +44(0)1865 248455
|
|
|
E-mail:
|
|
d.dalby@oxfordglobal.co.uk
|
|
|
|
|
|
|
|
|